by Paul | 29th April 2026 | News
Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator Raj Patil, PhD, Chief Scientific Officer, to present at ARVO London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing...
by Paul | 7th April 2026 | News
London and New York, NY, April 7, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it...
by Paul | 18th March 2026 | News
London and New York, NY, March 18, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new...
by Paul | 10th February 2026 | News
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantelli will lead the clinical and regulatory strategy to advance the...
by Paul | 30th January 2026 | News
London and New York, NY, January 30, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that...
